Cargando…
Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event
Aromatase inhibitors (AIs) are a commonly used antihormonal therapy in the treatment of breast cancer in postmenopausal women, specifically in the treatment of hormone receptor-positive breast cancer. AI-associated tendinopathy and muscle tendon rupture is exceedingly rare. Until now, only one case...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120376/ https://www.ncbi.nlm.nih.gov/pubmed/30186139 http://dx.doi.org/10.1159/000491874 |
_version_ | 1783352258026536960 |
---|---|
author | Mitsimponas, Nikolaos Klouva, Evangelia Tryfonopoulos, Dimitrios Grivas, Anastasios Demiri, Stamatina Koumakis, George Gouveris, Panagiotis |
author_facet | Mitsimponas, Nikolaos Klouva, Evangelia Tryfonopoulos, Dimitrios Grivas, Anastasios Demiri, Stamatina Koumakis, George Gouveris, Panagiotis |
author_sort | Mitsimponas, Nikolaos |
collection | PubMed |
description | Aromatase inhibitors (AIs) are a commonly used antihormonal therapy in the treatment of breast cancer in postmenopausal women, specifically in the treatment of hormone receptor-positive breast cancer. AI-associated tendinopathy and muscle tendon rupture is exceedingly rare. Until now, only one case with AI-associated severe tendinopathy has been reported in the medical literature, and there are no recorded cases of AI-associated muscle tendon rapture. We report three cases of postmenopausal women with hormone receptor-positive breast cancer, who experienced tendinopathy or muscle tendon rupture under antihormonal treatment with letrozole. All of the three women were in the adjuvant setting, and the treatment of tendinopathy or tendon rupture consisted of AI discontinuation, initiation of corticosteroids, or surgical treatment. Diagnosis was made via MRI. Furthermore, in our cases, there were no signs of underlying systemic disease, there was no abnormal physical activity preceding the complaints, and there was no use of other drugs beside letrozole. AIs are one of the most commonly used drugs in antihormonal therapy for hormone receptor-positive breast cancer. In every case of a female patient with hormone receptor-positive breast cancer under treatment with AIs and arthralgia, an MRI should be performed in order to exclude the presence of tendinopathy or muscle tendon rupture. |
format | Online Article Text |
id | pubmed-6120376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-61203762018-09-05 Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event Mitsimponas, Nikolaos Klouva, Evangelia Tryfonopoulos, Dimitrios Grivas, Anastasios Demiri, Stamatina Koumakis, George Gouveris, Panagiotis Case Rep Oncol Case Report Aromatase inhibitors (AIs) are a commonly used antihormonal therapy in the treatment of breast cancer in postmenopausal women, specifically in the treatment of hormone receptor-positive breast cancer. AI-associated tendinopathy and muscle tendon rupture is exceedingly rare. Until now, only one case with AI-associated severe tendinopathy has been reported in the medical literature, and there are no recorded cases of AI-associated muscle tendon rapture. We report three cases of postmenopausal women with hormone receptor-positive breast cancer, who experienced tendinopathy or muscle tendon rupture under antihormonal treatment with letrozole. All of the three women were in the adjuvant setting, and the treatment of tendinopathy or tendon rupture consisted of AI discontinuation, initiation of corticosteroids, or surgical treatment. Diagnosis was made via MRI. Furthermore, in our cases, there were no signs of underlying systemic disease, there was no abnormal physical activity preceding the complaints, and there was no use of other drugs beside letrozole. AIs are one of the most commonly used drugs in antihormonal therapy for hormone receptor-positive breast cancer. In every case of a female patient with hormone receptor-positive breast cancer under treatment with AIs and arthralgia, an MRI should be performed in order to exclude the presence of tendinopathy or muscle tendon rupture. S. Karger AG 2018-08-17 /pmc/articles/PMC6120376/ /pubmed/30186139 http://dx.doi.org/10.1159/000491874 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Mitsimponas, Nikolaos Klouva, Evangelia Tryfonopoulos, Dimitrios Grivas, Anastasios Demiri, Stamatina Koumakis, George Gouveris, Panagiotis Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event |
title | Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event |
title_full | Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event |
title_fullStr | Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event |
title_full_unstemmed | Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event |
title_short | Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event |
title_sort | aromatase inhibitor-associated tendinopathy and muscle tendon rupture: report of three cases of this exceedingly rare adverse event |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120376/ https://www.ncbi.nlm.nih.gov/pubmed/30186139 http://dx.doi.org/10.1159/000491874 |
work_keys_str_mv | AT mitsimponasnikolaos aromataseinhibitorassociatedtendinopathyandmuscletendonrupturereportofthreecasesofthisexceedinglyrareadverseevent AT klouvaevangelia aromataseinhibitorassociatedtendinopathyandmuscletendonrupturereportofthreecasesofthisexceedinglyrareadverseevent AT tryfonopoulosdimitrios aromataseinhibitorassociatedtendinopathyandmuscletendonrupturereportofthreecasesofthisexceedinglyrareadverseevent AT grivasanastasios aromataseinhibitorassociatedtendinopathyandmuscletendonrupturereportofthreecasesofthisexceedinglyrareadverseevent AT demiristamatina aromataseinhibitorassociatedtendinopathyandmuscletendonrupturereportofthreecasesofthisexceedinglyrareadverseevent AT koumakisgeorge aromataseinhibitorassociatedtendinopathyandmuscletendonrupturereportofthreecasesofthisexceedinglyrareadverseevent AT gouverispanagiotis aromataseinhibitorassociatedtendinopathyandmuscletendonrupturereportofthreecasesofthisexceedinglyrareadverseevent |